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University of Denver, Denver, Colorado; and §Stony Brook University, Stony Brook, New YorkABSTRACT We develop a theory for three states of equilibrium of amyloid peptides: the monomer, oligomer, and fibril. We
assume that the oligomeric state is a disordered micellelike collection of a few peptide chains held together loosely by hydro-
phobic interactions into a spherical hydrophobic core. We assume that fibrillar amyloid chains are aligned and further stabilized
by steric zipper interactions—hydrogen bonding, steric packing, and specific hydrophobic side-chain contacts. The model
makes a broad set of predictions that are consistent with experimental results: 1), Similar to surfactant micellization, amyloid
oligomerization should increase with peptide concentration in solution. 2), The onset of fibrillization limits the concentration of
oligomers in the solution. 3), The extent of Ab fibrillization increases with peptide concentration. 4), The predicted average fibril
length versus monomer concentration agrees with data on a-synuclein. 5), Full fibril length distributions agree with data on
a-synuclein. 6), Denaturants should melt out fibrils. And finally, 7), added salt should stabilize fibrils by reducing repulsions
between amyloid peptide chains. It is of interest that small changes in solvent conditions can tip the equilibrium balance between
oligomer and fibril and cause large changes in rates through effects on the transition-state barrier. This model may provide useful
insights into the physical processes underlying amyloid diseases.INTRODUCTIONWhat are the forces that stabilize aggregates of amyloid
peptide molecules? This question is of interest because of
the putative role played by amyloid aggregation in diseases
such as Alzheimer’s, Parkinson’s, Mad Cow, and type II
diabetes (1). Amyloid appears to aggregate into at least
two different states: amyloid oligomers, which are small,
few-chain soluble disordered clusters, and fibrils, which
are long, many-chain highly structured b-sheet-like aggre-
gates. The view has recently emerged that the oligomers
may be the toxic species, not the fibrils, as had been
expected because of the appearance of plaques in disease
(2). It has been challenging to understand the physical prin-
ciples of amyloid aggregation, in part because of a lack of
reductionist experimental model systems. In this regard,
we believe that simple models can help guide and interpret
experiments.
The first challenge is to discover the extent to which
amyloid properties can be explained by equilibrium versus
kinetics. Kinetics is often easier to study experimentally
because measurement of rates does not require establishing
conditions of reversibility. Yet, there is experimental
evidence of multiple stable states: monomers, oligomers,
and fibrils, and perhaps a precursor to the fibrillar state
called the protofilament (3). We believe insights can be
gained from first understanding the underlying phase equi-
libria. A key question is whether or not these observed states
are truly stable equilibrium states. It is not always clear.
However, we take the view here that the fact that these states
are observable on the experimental timescale is evidenceSubmitted August 30, 2010, and accepted for publication November 9, 2010.
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0006-3495/11/01/0450/9 $2.00that such states are at least metastable. This is a sufficient
basis for our modeling here. In this work, we cannot say
much about kinetic barriers or timescales; our more modest
aim here is to address states that are at least persistent
enough to have been observed in experiments.
Various approaches to modeling amyloid aggregation
have been taken by others. Algorithms have been developed
to determine which amino acid sequences have the propen-
sity to aggregate (4–7). Kinetics models and mass-action
models have been proposed to understand the nucleation
process and rates of fibril formation (8–13). Here, our focus
is different: we are interested in physical equilibria.
Closer in spirit to our focus in this study are models of
monomer-fibril equilibria (14–16), but these do not treat
smaller soluble oligomers, an additional equilibrium that
of key interest to us here. Equilibrium with oligomers has
been treated using the thermodynamic models of Lee (17)
and Tiana et al. (18). Here, our approach is more micro-
scopic, and we provide a more microscopic interpretation
using statistical thermodynamics.
Our work resembles the grand canonical treatment of Lee
(17) for the three states, but it goes further in the following
respects. First, we make an effort to give a microscopic
interpretation of the energies and entropies involved in
terms of hydrogen-bonding and zipping interactions.
Second, whereas Lee’s work focuses on the effects of
temperature and pressure, our work focuses on salt, denatur-
ants, and peptide precursor, which, we believe, are more
critical to experimental study. Third, our article touches
extensively on the broad range of existing experimental
data, an important step in validating a model and developing
meaningful parameters for realistic systems.doi: 10.1016/j.bpj.2010.11.041
Amyloid and Oligomer Thermodynamics 451MODELING THE STATES OF AMYLOID
AGGREGATION
We develop here a model of the equilibrium among the
following states: 1), isolated monomeric amyloid peptide
molecules in solution; 2), few-chain noncovalent aggregates
(oligomers) of amyloid peptide molecules; 3), the single
macroscopic thread, called a protofilament, which is a non-
covalent ordered assembly of many chains; and 4), the fibril,
which is a bundle of protofilaments. These states are shown
in Figs. 1 and 2. Fig. 2 is a reference key to help in trans-
lating between molecular structures and the simplified brick
diagrams we use here. (In this article, the term monomer
refers to an individual peptide chain, not to a single amino
acid in a chain (Fig. 1 a)) (3,19,20). Our interest here is in
peptides, such as Ab, a-synuclein, and islet amyloid poly-
peptide, that do not have single-chain native folded struc-
tures, so our model below neglects any possible additional
equilibria with a native folded structure.Modeling the oligomer state
Our model of the oligomer state is shown in Fig. 1 a. Olig-
omers are known to range in size from trimers to hundreds
of monomers (3,19–25). We model the amyloid oligomer
state as a disordered spherical globule with a hydrophobic
core containing N peptide chains. Each chain has L amino
acids. We approximate the free energy of oligomerization,
DFoligo, from state A to state B (Fig. 1) in terms of the trans-A B C
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FIGURE 1 (Upper) Model of amyloid aggregation equilibria. Each black line
(State A) Isolated peptide monomers in solution. (State B) Oligomeric assembly
backbone runs perpendicular to the fiber axis. (State D) Postcritical nucleus stru
thread of b-structure consisting of a b-sandwich and two face-to-face b-sheet plan
p ¼ 2 protofilament threads. (Lower) Schematic representations of the free-energ
concentrations, as described by our model. Labels correspond to the states depi
energy minimum, whereas at high concentrations, the fibril (State F) is the minim
relative stabilities of the fibril and oligomer states.fer of the NL amino acids from water into the oligomeric
core as (26,27)
DFoligo ¼ DFAB
kT
¼ cNL; (1)
where kTc is the free energy of transfer per amino acid and
c is the Flory-Huggins parameter, averaged over the amino
acid composition of the peptide and over the solvent acces-
sibilities of the various amino acids. Following recent work
(28), we neglect the distinction between interior and surface
residues that was drawn in older models (26).Modeling the protofilament and its nucleus
A common feature of amyloid aggregates observed in NMR
and x-ray structures is the b-sandwich motif (Fig. 2 c)
(29–33). Here, we assume that the basic structural element
of protofilaments and fibrils is the b-sandwich. Before
describing our fibril model, we define our terminology for
structures that appear throughout this article. A b-strand is
a single linear stretch of peptide chain. A b-sheet is
comprised of two or more hydrogen-bonded b-strands (see
Fig. 2, a and b). A b-sandwich is two planar b-sheets
face-to-face (see Fig. 2 c). For example, in the fibrillar state
the Ab molecule is a V-shaped b-hairpin comprised of two
b-strands. In amyloid fibrils, the b-sandwich is stabilized by
H-bonds parallel to the fibril axis and by hydrophobic and
van der Waals interactions from the interdigitation of sideE F
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indicates the peptide backbone. Each red line represents one hydrogen bond.
of a few peptide chains. (State C) Nucleus of b-sheet structure. The peptide
cture showing more b-structure. (State E) A protofilament is a single long
es. (State F) The full fibril, a bundle of protofilaments shown here to contain
y (F) landscape at low (left), intermediate (middle), and high (right) peptide
cted above. At low concentrations, the monomer state (state A) is the free-
um. At intermediate concentrations, the solution depends sensitively on the
Biophysical Journal 100(2) 450–458
FIGURE 2 Assembly hierarchy of amyloid fibrils shown in atomistic
cartoon representation (left) and schematically, with b-sheets as blocks
(right). (a) A single b-sheet comprised of parallel b-strands. (b) A b-sheet
observed along the fibrillization axis. (c) Assembled b-sandwich (protofila-
ment) consisting of two b-sheets. Note the steric zipper interactions shown
as interdigitating side chains (left) and as a green layer (right). (d) Mature
fibril consisting of p ¼ 2 protofilaments.
452 Schmit et al.chains within the steric zipper between the two b-strands
(see Fig. 2 c) (29). At a given stage of fibrillization, we
assume that a b-sheet is composed of h b-strands. Each
b-strand contributes b amino acids to the b-sheet. The sheet
width b must satisfy b% ‘, where ‘% L is the length of the
b-strands in the mature fibril. At a given stage of fibril
formation, the total number of residues in the b state is
m ¼ 2bh, where the factor of 2 accounts for the two sheets
in the b-sandwich. The quantities b and h are shown sche-
matically in Fig. 1, c and d. The quantity m serves as an
order parameter for the extent of fibril formation.
We treat cooperative fibril formation in a way that resem-
bles the standard treatment of the helix-coil transition in
peptides (34–38). We call states BCDE the fibril-ordering
pathway. The free energy as a function of m is
DFBCDEðmÞ
kT
¼ cðNL mÞ  mlngs 
ﬃﬃﬃﬃ
m
2
r
lng; (2)
where m is the order parameter or reaction coordinate along
the route BCDE. m ranges from m ¼ 0 when the system is
fully disordered (i.e., fully in state B), to m ¼ NL when
the system is fully ordered in the b-state (i.e., fully in
state E). (Thus, in normalized form, a reaction coordinateBiophysical Journal 100(2) 450–458could be expressed as x ¼ m/NL). The first term in Eq. 2
is the free energy of converting m of the NL amino acids
from their oligomeric disordered state, with a corresponding
loss of the disordered micellelike hydrophobic interactions.
The second term in Eq. 2, mlngs, is the free energy of
forming a b-sandwich containing m amino acids. gs is
a dimensionless propagation equilibrium coefficient that
resembles the helix propagation quantity s in helix-coil
theories (34,37), except that gs here describes b-structure,
not a-helical structure. gs captures various types of interac-
tions, including conformational entropy, hydrogen bonds,
steric packing, and ordered side-chain hydrophobic interac-
tions. A necessary condition for fibril formation is gs > 1.
That is, fibrils can only form when the sterically zippered
state (hydrogen bonds, packing, and ordered hydrophobic
interactions) is more favorable than the monomeric state.
In this case, the subscript s in gs indicates an interaction
within a single b-sandwich, not interactions between the
different b-sandwiches that make up a full fibril.
We treat the cooperative formation of fibrils as a surface/
interior nucleation process. The third term in Eq. 2,ﬃﬃﬃﬃﬃﬃﬃﬃ
m=2
p
lng, is the free energy of initiating steric zipping at
the edge of the b-sandwich (a square having m/2 residues
has a perimeter with
ﬃﬃﬃﬃﬃﬃﬃﬃ
m=2
p
residues). In our model, g is
a surface tension for forming the perimeter bonding. In
the metaphor of helix-coil theories, g resembles s, the
helix-coil nucleation parameter. Fig. 1 shows that the edge
of the b-sandwich has 2b unsatisfied H-bonds, but only
b unsatisfied hydrophobic contacts due to the stagger
between the two sheets. It is these missing hydrophobic
and H-bond interactions that account for why there should
be a barrier, g < 1, to nucleating the fibril. This nucle-
ation-barrier free energy in Eq. 2 is maximal for b ¼ ‘.
At the current stage of knowledge of microscopic structures,
this square-shape approximation has the advantage of
simplicity and is adequate to capture the shift in the olig-
omer-fibril growth transition from hydrophobic to combined
hydrophobic and hydrogen-bonding interactions (39).
This model gives insight into fibril formation rates. We
compute the free energy of the fibril-formation transition
state by finding the maximum value of DForder along the
reaction coordinate m using Eq. 2. The transition state is
at DFz ¼ ðdDForder=dmÞm ¼ 0, so
DFz
kT
¼ DForderðm
Þ  DForderð0Þ
kT
¼ ln
2g
8ðlnðgsÞ  cÞ: (3)
Equation 3 shows that the free-energy barrier can depend
strongly on small changes in the intermolecular interactions,
since the denominator contains the difference quantity
ln(gs) – c, which will be small. The quantities lngs and c
are dimensionless quantities of order unity; their difference
is small, because the zipping free energy is expected to be
only slightly more favorable than amorphous hydrophobic
interactions. Small variations in gs or c, at the level of single
Amyloid and Oligomer Thermodynamics 453amino-acid changes or slight changes in solution conditions,
could change fibrillization rates by several orders of magni-
tude (40). This provides a rationale for understanding how
a single mutation could transform a normal fibrillization
rate, which might be too slow to cause disease in a human
lifetime, into a much faster fibrillization rate sufficient to
cause disease during a human lifetime.
Our model of the amyloid nucleation process differs from
classic nucleation mechanisms in two respects: 1), it
involves a one-dimensional line tension (41), rather than
a two-dimensional surface tension; and 2), our ordering
transition is from oligomers to fibrils, not from monomers
to aggregates, so our fibrillization mechanism is not driven
by increasing the solution concentration of monomers.
This is consistent with experiments showing that amyloid
nucleation is concentration-independent (42). The proposed
explanation in the nucleated conformational conversion
model (42) is that oligomeric chains must enter an activated
conformation to proceed to fibrils. In our model, the role of
activation is played by the entropically unfavorable steric-
zipper nucleus. This activation step is shown qualitatively
as the barrier between states B and D in the free-energy
landscapes depicted in Fig. 1.FIGURE 3 Schematic representation of the parameter ns. Here, each
peptide chain contributes one (a), two (b), and four (c) b-strands to the
fibril. For clarity, adjacent peptide chains are shown in alternating colors.Modeling the full fibril
We treat a full fibril as a collection of p b-sandwich-motif
protofilaments stacked and bundled together. Fig. 1 e shows
such a fibril for p ¼ 2. DFEF is the free energy of bundling
protofilaments into fibrils,
DFbundling
kT
¼ DFEF
kT
¼ nLe ¼ nLln

g
gs

; (4)
where L is the number of amino acids per peptide chain, n is
the number of peptide chains in the bundled fibril, and g is
the propagation constant for forming b-structure in the
mature fibril. Equation 4 gives lng ¼ lngs þ 3, so lngs
is the free energy of the interactions within a single protofi-
lament, and 3 is the interaction energy holding different pro-
tofilaments together. Because these bundling interactions
occur only between a subset of residues on the perimeter
of the protofilament, we expect that g and gs will be approx-
imately equal.
Within a fibril, a single peptide molecule is sometimes
folded back and forth, so it contributes multiple b-strands
to the fibril. To account for this, we introduce the parameters
‘, the length of each b-strand, and ns, the number of
b-strands formed by each peptide chain. For example,
peptides such as Ab and islet amyloid polypeptide that
form a single hairpin in the mature fibril have ns ¼ 2. These
quantities are related by L ¼ ns‘ (see Fig. 3).
From Eq. 2, it is clear that each protofilament incurs
a nucleation penalty kT‘lng and that each b-strand in
the fibril contributes a binding energy kT‘lng. However,a more convenient quantity is the binding energy/peptide,
kT‘nslng¼kTLlng. The free energy of a fibril consisting
of n peptides is then
DFn
kT
¼ DFAF
kT
¼ lngp‘gnL: (5)
The fibrillization index n must be greater than the minimum
fibril size n0. However, we find that the physical observables
are insensitive to the precise value of n0 (see the Supporting
Material). This is in contrast to the oligomer size N, which
has a strong affect on phase behavior.The monomer-oligomer-fibril assembly
equilibrium
Now, we combine the stepwise free energies above into
a grand canonical ensemble to determine how the assembly
equilibria depend on the concentration of peptide monomers
in solution. If the oligomeric state resembles a micelle,
a reasonable approximation is that the oligomer species is
dominated by a single aggregation number, with free energy
given by Eq. 1. However, for the fibril, we assume
a continuum of aggregation states with n peptide chains
and a free energy given by Eq. 5. To compute the properties
of the solution, we compute the binding polynomial (43):Biophysical Journal 100(2) 450–458
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FIGURE 4 Phase diagram for peptides with p, ns ¼ 1, ‘ ¼ 15, N ¼ 10,
lng ¼ 0.6, and lng ¼ 2 as a function of peptide concentration and lng/c.
Lines depict phase boundaries computed from Eq. S12 (long-dashed), Eq.
S8 (short-dashed), and Eq. S4 (solid). Colors (colored figure available
online) show the numerical solution of Eq. 7 as follows: green¼c1/c0 (mono-
mers); blue ¼ coligo/c0 (oligomers); and red ¼cfibril/c0 (fibrils).
454 Schmit et al.Q ¼ c1 þ cN1 ecNL þ gp‘
X
n
c1
ngnL; (6)
In Eq. 6, c1 is the concentration of monomers, c1
NecNL is the
concentration of oligomers, and the final term is the sum
over the concentrations of fibrils of all possible lengths.
The total peptide concentration, c0, can be computed using
the concentration of each species and summing the number
of peptides in each species. Thus, c0 is written as
c0 ¼ dQ
dlnc1
¼ c1 þ NcN1 ecNL þ gp‘
XN
n¼ n0
ncn1g
nL; (7)
where n0 is the smallest accessible fibril size.
The solution-phase behavior is given by the peptide
concentrations in each of three states: monomer, c1; olig-
omer, coligo; and fibril, cfibril, where
coligo ¼ NcN1 ecNL (8)
and
cfibril ¼ gpl
XN
n¼ n0
ncn1g
nL (9)
are the component terms fromEq.7.The three relative concen-
tration quantities c1/c0, coligo/c0, and cfibril/c0 must sum to 1.
It should be noted that both coligo and cfibril are exponentially
sensitive to the peptide length, L. To compute the phase
diagram, we numerically solve Eq. 7 for c1 at fixed values of
c0, g, g, and c. The concentrations of peptides in the fibril
and oligomer states are then computed from Eqs. 8 and 9.
The model predictions are given below. Fig. 1 shows the
energy landscape for aggregation and the corresponding local
minima. The figure also shows how changing the peptide
concentration tilts the landscape, stabilizing various states.
We also show below how other factors, such as denaturants
or pH or salts, affect the relative stabilities of the minima.RESULTS
The model predicts an amyloid triple point,
a three-state equilibrium
Fig. 4 shows the phase diagram computed from Eq. 7. The x
axis shows the monomer concentration. The y axis shows
lng/c, the ratio of the free energy for a steric zipper to the
free energy for amorphous hydrophobic aggregation, for
a fixed value of g. The boundaries in Fig. 4 represent the
conditions of equal populations of the two corresponding
states. In the Supporting Material, we derive analytic
expressions for the phase boundaries. These are shown in
Fig. 4 by black lines.
The model predicts three main features. First, increasing
the amyloid peptide concentration in solution leads to
increased aggregation (for both oligomers and fibrils).
Second, we were not surprised to find, at high peptideBiophysical Journal 100(2) 450–458concentrations, changing solution conditions to favor steric
zipping tips the balance from oligomers toward fibrils. This
phase equilibrium line is relatively flat, indicating that it is
not very dependent on monomer concentration. Third, there
should be a triple point, a particular monomer concentration
and solution condition at which monomers, oligomers, and
fibrils are all present in equal populations.
The phase diagram can be closely approximated by
comparing the critical fibril concentration (CFC) to the
critical oligomer concentration (COC) (see Supporting
Material). The lesser of these two quantities determines
the aggregate species that appears upon raising the peptide
concentration. However, if the COC is less than the CFC,
it may be possible to drive the solution from the oligomer
state to the fibril state by further raising the peptide concen-
tration. This transition may be computed using the fibril-
oligomer coexistence condition (see Eq. S12 and
Eq. S26). The converse is not true; it is not possible to reach
the oligomer phase from the fibril phase by increasing the
peptide concentration. This asymmetry arises from differ-
ences in the ability of the oligomer relative to that of the
fibril to buffer the monomer concentration. The fibril has
an essentially infinite buffering capacity (required for the
convergence of Eq. 7), and thus, the CFC sets a hard limit
on the achievable monomer concentration. On the other
hand, the monomer concentration will still rise, albeit
weakly, upon reaching the COC, and therefore, it is possible
for the monomer concentration to reach the CFC even after
oligomers have begun to form, provided the CFC is not
much greater than the COC.When fibrils are stable, oligomers are not
It is interesting to note that the model predicts that amyloid
peptide will be soaked up into the fibrils and depleted
from the oligomers, with increasing bulk peptide con-
centration. To see this, substitute the CFC (Eq. S4) into
Eq. 8 to get
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This small quantity, e–(lng–c) < 1, is raised to a large power,
LN. Thus, unless c and lng are closely matched, the concen-
tration of the oligomeric state will be negligible under fibril-
forming conditions. The implication for disease is that if
oligomers are toxic, promoting fibril formation may deplete
the toxins. In essence, the fibril acts as a buffer that controls
and limits the pool of oligomers.FIGURE 6 Average length of fibrils versus peptide concentration, and in
comparison to experiments on a-synuclein (46). Llng ¼ 15.5 and
‘plng ¼ 32.3.Fibril concentration increases as a nonlinear
function of monomer concentration
Fig. 5 shows how the predicted fibril population, cfibril,
depends on peptide concentration compared with the exper-
iments of Terzi et al. (44). Since the N-terminal 11–16 resi-
dues of Ab40 are disordered (30,45) in the fibril state, we
take L¼ 26. To fit the data, we neglect the oligomer popula-
tion and convert the experimental concentration, cM (inmolar
units), to the dimensionless concentrations required in our
treatment. As a simple approximation, we divide by the
molarity of water to get c ¼ (cM/55.5M). From that fit, we
find thatLlng¼13.1 andp‘lng¼ 15.5 at experimental
conditions 278 K and pH 7.4. In the next section, we find
similar parameters for a-synuclein fibrils.Fibril lengths undergo a growth transition versus
monomer concentration
Now we compute the distribution of fibril lengths. The prob-
ability that a fibril has a length n, P(n), is given by
PðnÞ ¼ c
n
1g
nLP
i c
i
1g
iL
: (11)
What are the average fibril lengths? In the Supporting
Material, we show that the average length scales as
c0
1/2g–‘p/2, in agreement with the concentration dependence
found by Lee (17). Fig. 6 shows the fit of Eq. 7 (neglectingFIGURE 5 Plot of cfibril as a function of the bulk peptide concentration
compared to circular dichroism data of Terzi et al. for Ab1–40 (44). L ¼
26, ns ¼ 2, p ¼ 2, g ¼ 1.66, and g ¼ 0.54.the oligomer term) and Eq. S14 compared to the average
fibril-length measurements of van Raaij et al. (46). From
the fit we find, gL, which determines the onset of fibrilliza-
tion, and we find g‘p, which determines the fibril length. We
obtain Llng ¼ 15.5 and ‘plng ¼ 32.3. In a-synuclein
fibrils, it is found that p ¼ 4, twice the value for Ab fibrils
(46). Allowing for this factor of 2, the values of Llng and
‘lng are quite similar to those determined for Ab in the
previous section. ns and ‘ are not yet known for a-synuclein.
Fig. 7 demonstrates the prediction that fibril lengths
follow an exponential distribution, which is in quantitative
agreement with experimental data (see Eq. S14).Denaturants destabilize the fibrils and oligomers
What is the effect of denaturants and osmolytes on amyloid
aggregation? First, because both oligomers and fibrils are
stabilized by hydrogen-bonding and hydrophobic interac-
tions, denaturants should melt out all types of amyloid
aggregated states. A more subtle question is how denatur-
ants shift the oligomer-fibril equilibrium. Fig. 8 shows the
model predictions that 1), denaturants such as urea, not
unexpectedly, should weaken hydrophobic and hydrogen
bonding interactions, disrupting aggregation; 2), more dena-
turant is required to disrupt aggregates if the amyloid
concentration is high; and 3), adding denaturant to fibrils
can drive the system into the oligomer state.
We make three additional points. First, in apparent
contradiction to this prediction, denaturants are sometimes
used to promote fibrillization, but that appears to be
observed exclusively in systems that have a native folded
state (47–49), unlike those modeled here. Second, this
model resolves a paradoxical result in the literature. Chen
and Glabe found that urea drove fibrils to melt directly to
monomers without passing through the oligomer state
(19). In contrast, Kim et al. found that urea drove fibrils to
melt to oligomers, which then melted to monomers (50).
Fig. 8 gives an explanation: the Ab peptide concentrationsBiophysical Journal 100(2) 450–458
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FIGURE 7 Comparison of the computed fibril length distribution as
a function of the bulk peptide concentration to the experimental distribu-
tions of a-synuclein for peptide concentrations ranging from 20 to
250 mM (46). Llng ¼ 15.5 and ‘plng ¼ 32.3.
TABLE 1 Computed fraction of peptide in the fibril phase
compared to experiment
Experiment (50) Theory
[Urea] Oligomer fraction Fibril fraction Fibril fraction
0.4 M 0 0.37 0.30
2 0.37* 0.03
4 0.2 0 103
6 0.22 0 105
Experimental data are taken from Kim et al. (50).
*Aggregate fraction was observed to be a combination of fibrils and oligo-
mers.
456 Schmit et al.used by Kim et al. were 3- to 10-fold greater than those used
by Chen and Glabe, shifting to a region of the phase diagram
in which oligomers are a stable intermediate phase. Finally,
our model predicts the fraction of aggregates as a function of
denaturant concentration, which is in good agreement with
data (see Table 1) (50).FIGURE 8 Phase diagram for Ab as a function of peptide concentration
and urea concentration. The colors represent monomers (green), oligomers
(blue), and fibrils (red). N ¼ 4 and cNL ¼ 36.4 (19), and all other param-
eters are identical to those in Fig. 5. This diagram explains a discrepancy
between the experiments of Chen and Glabe (19) and Kim et al. (50).
The black line indicates the denaturation pathway of Chen and Glabe,
who found no intermediate oligomers. For the Kim experiments, denatur-
ation is indicated by the white line and shows an oligomeric state at inter-
mediate urea concentrations.
Biophysical Journal 100(2) 450–458Electrostatic repulsion destabilizes the fibrils
To treat the effects of pH and salt, we express the binding
free energy g as
Llngðq; csÞ ¼ Llng0 þ DFesðq; csÞ; (12)
in terms of g0, which accounts for the binding energy for
a reference peptide having zero net charge, and an electro-
static component, DFes, which is the free energy of charging
up the peptides from their uncharged state to a net charge q
in the presence of a salt concentration cs. The latter is given
quantitatively by Eq. S31.
Fig. 9 compares the calculated electrostatic repulsions
with experimental measurements of dependence of the crit-
ical concentration on salt concentration. We identify the crit-
ical concentrations with the theoretical quantity c1
(CFC),
which we compute using Eq. 12. We compute charges of
q¼3.9 at pH 9.0 and q¼2.8 at pH 7.4 for the Ab peptide
(51). We treat each fibril as a cylinder of radius R ¼ 10 nm
(52) using Poisson-Boltzmann theory (see Eq. S31). Fig. 9
shows a comparison of the experiments on the Ab40 system
by Klement et al. for pH 9 (52) and Terzi et al. for pH 7.4
(44). The sole fitting parameter in Fig. 9 (obtained from the
Klement data (52)) is Llng0 ¼ 21.9. This corresponds
to Llng ¼ 15.5 under the conditions of Terzi et al. of
pH 7.4 and 5mM. This is consistent with our earlier estimate,
Llng¼13.1, particularly given the extreme sensitivity of
the electrostatic free energy at such low salt concentrations.FIGURE 9 Predicted solubility of Ab40 as a function of salt concentra-
tion and net peptide charge. Data points at q ¼ 3.9 are from Klement
et al. (52) and the point at q ¼ 2.8 is from Terzi et al. (44).
Amyloid and Oligomer Thermodynamics 457CONCLUSIONS
We have described an equilibrium theory for the aggrega-
tion of short peptides into globular and fibrillar aggregates.
The model predicts two transitions: 1), a micellelike transi-
tion of monomeric peptides in solution to an oligomeric
state, involving a loose hydrophobic core and a loss of trans-
lational entropy, and 2), a transition from the disordered
globular oligomeric state to an ordered b-structured fibrillar
state, driven by tighter packing, hydrogen bonding, and
steric and hydrophobic interactions.
We find good agreement of the model with experiments
on fibril concentrations, average fibril lengths, and fibril
length distributions versus monomer concentrations. We
find that the phase boundaries and transition states are
highly sensitive to small changes in solution conditions
and protein properties. Such sensitivities may be relevant
to aggregation processes in amyloid diseases.SUPPORTING MATERIAL
Thirty-one equations, one figure, and additional references are available at
http://www.biophysj.org/biophysj/supplemental/S0006-3495(10)01439-6.
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